Prestige Consumer Healthcare In
PBH
Positions held
Your positionsPBH isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Prestige Consumer Healthcare operates in a competitive healthcare sector with a focus on specialty and generic drug manufacturing, which positions it well for growth as demand for affordable healthcare solutions rises.
- The company has a market cap of approximately $2.2 billion and a forward P/E ratio of 9.14, indicating potential undervaluation compared to industry peers.
- In 2026-Q1, Prestige reported revenue of $281.617 million, with an operating margin of 26.8%, showcasing strong profitability.
- The company faces challenges with declining earnings growth, which may impact investor confidence and future performance.
- In the most recent quarter, revenue decreased by 6% compared to the prior quarter, falling from $282 million to $266 million.
- The quarterly score indicates a 'Sell' signal with a score of -10.00, reflecting negative trends in key performance indicators.
Fundamentals
| Market cap | $2.27B | Enterprise value | $4.25B | Trailing P/E | 13.41 | Forward P/E | 9.42 |
| PEG | 1.50 | Price / book | 1.18 | Beta | 0.34 | Dividend yield | 0.00% |
| Revenue growth | 6.5% | Earnings growth | -35.8% | Gross margin | 54.8% | Operating margin | 20.8% |
| Profit margin | 15.6% | ROE | 9.1% | ROA | 4.6% | Debt / equity | 1.08 |
| Current ratio | 3.23 | Free cash flow | $147.89M | Analyst recommendation | buy | Mean target | $67.80 |
| 52w high | $71.07 | 52w low | $42.62 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $266M | $282M | $283M | $274M | $250M |
| Op margin | 19.8% | 26.8% | 29.1% | 29.1% | 28.8% |
| Net income | $29.2M | $53.9M | $46.7M | $42.2M | $47.5M |
| Gross margin | 51.3% | 51.9% | 55.5% | 55.3% | 56.2% |
| Gross profit | $136M | $146M | $157M | $152M | $140M |
| Operating income | $52.5M | $75.5M | $82.5M | $79.7M | $71.8M |
- Revenue -6% vs prior quarter ($266M vs $282M).
- Gross margin 51.3% (was 52% prior quarter).
- Operating margin compressed to 19.8%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B | — |
| Op margin | 28.4% | 30.7% | 30.4% | 30.8% | — |
| Net income | $190M | $215M | $209M | -$82.3M | — |
| Gross margin | 54.7% | 55.8% | 55.5% | 55.4% | — |
| Gross profit | $596M | $634M | $624M | $625M | — |
| Operating income | $309M | $349M | $342M | $348M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Best Value Stocks to Buy for October 1st
2026-09-30 · PBH vs. NEOG: Which Stock Is the Better Value Option?
2026-09-29 · Has Prestige Consumer Healthcare (PBH) Fallen Far Enough On Earnings?
2026-09-29 · Prestige Consumer Healthcare (PBH) Could Be 30% Undervalued After Its 2027 Targets
2026-09-27 · Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow
2026-09-14 · PBH or NEOG: Which Is the Better Value Stock Right Now?
2026-09-08 · Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference
2026-09-02 · Is This the Right Time to Add PBH Stock to Your Portfolio?
2026-09-01 · Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test
2026-08-28 · PBH vs. SYK: Which Stock Is the Better Value Option?
2026-08-13 · Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?
Price (daily)
Full chart · RSI · MACD · patterns